Xcout Intel
Immitra Bio
Immitra Bio GmbH is a biotechnology startup and ETH Zürich spin-off developing a scalable in-vivo genetic medicine platform to treat rare genetic diseases. Headquartered in Schlieren, Switzerland, the company secured early-stage venture funding to advance its gene-editing therapies.
Subscribe to see Immitra Bio’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Immitra Bio at a glance
Immitra Bio is a drug discovery company headquartered in Switzerland. Its most recent funding round, Pre-Seed, raised $3M in July 2026. Xcout tracks 2 named people at Immitra Bio, including Jan Nelis (Co-founder and Chief Executive Officer).
Immitra Bio leadership
- Jan NelisCo-founder and Chief Executive Officer
- Amir TaheriCo-founder and Chief Scientific Officer
Immitra Bio funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Pre-Seed | $3M | 8 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Immitra Bio competitors
A few of Immitra Bio's closest competitors — see the full list of competitors and alternatives →
Cassidy Bio is an AI-first biotechnology company founded in 2024 and based in Israel that is developing a programmable platform for gene editing. The company utilizes a genomic foundation model powered by artificial intelligence to design safer and more scalable gene editing therapies across various guides, editors, and delivery contexts.
AIRNA Corp is a biotechnology company headquartered in Cambridge, Massachusetts, focused on developing RNA editing therapeutics. Its leading program utilizes ADAR-recruiting technology to target specific RNA locations for therapeutic applications.
Eurus Therapeutics is a biotechnology startup headquartered in Fujisawa, Kanagawa Prefecture, Japan. Founded in 2021, the company is building an advanced drug-discovery platform based on a novel genome-editing technology called Eurus Editor.
Scout Bio, Inc. is a veterinary biotechnology company specializing in animal health and advanced gene therapy treatments currently being evaluated in clinical trials.
Glycomine, Inc. is a biotherapeutics company focused on developing replacement therapies and treatments for serious rare genetic diseases, operating out of major life science hubs in San Francisco and Boston.
VectorY Therapeutics is a fully integrated gene therapy company founded in August 2020 and based in Amsterdam, Netherlands. The company is focused on developing novel gene therapies, including clinical trials for conditions like amyotrophic lateral sclerosis (ALS).
Get Immitra Bio's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Immitra Bio in Xcout Intel
- 2 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access